Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer.

Ando C, Ichihara E, Kano H, Iwamoto Y, Hirabae A, Nakasuka T, Maeda Y, Kiura K.

In Vivo. 2019 Nov-Dec;33(6):2113-2115. doi: 10.21873/invivo.11711.

PMID:
31662545
2.

Patients' preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406.

Makimoto G, Hotta K, Oze I, Ninomiya K, Nakanishi M, Hara N, Kano H, Watanabe H, Hata Y, Nishii K, Nakasuka T, Itano J, Ninomiya T, Kubo T, Ohashi K, Ichihara E, Minami D, Sato A, Tabata M, Maeda Y, Kiura K.

Acta Oncol. 2019 Oct 25:1-5. doi: 10.1080/0284186X.2019.1679880. [Epub ahead of print] No abstract available.

PMID:
31650873
3.

Managing Lung Cancer with Comorbid Interstitial Pneumonia.

Ichihara E, Miyahara N, Maeda Y, Kiura K.

Intern Med. 2019 Sep 18. doi: 10.2169/internalmedicine.3481-19. [Epub ahead of print]

4.

Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia.

Ogura T, Takigawa N, Tomii K, Kishi K, Inoue Y, Ichihara E, Homma S, Takahashi K, Akamatsu H, Ikeda S, Inase N, Iwasawa T, Ohe Y, Ohta H, Onishi H, Okamoto I, Ogawa K, Kasahara K, Karata H, Kishimoto T, Kitamura Y, Gemma A, Kenmotsu H, Sakashita H, Sakamoto S, Sekine K, Takiguchi Y, Tada Y, Toyooka S, Nakayama Y, Nishioka Y, Hagiwara K, Hanibuchi M, Fukuoka J, Minegishi Y, Yanagihara T, Yamamoto N, Yamamoto H, Gaga M, Fong KM, Powell CA, Kiura K; DLD/TO Assemblies of JRS.

Respir Investig. 2019 Nov;57(6):512-533. doi: 10.1016/j.resinv.2019.06.001. Epub 2019 Aug 1. Review.

PMID:
31377122
5.

Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.

Makimoto G, Ohashi K, Tomida S, Nishii K, Matsubara T, Kayatani H, Higo H, Ninomiya K, Sato A, Watanabe H, Kano H, Ninomiya T, Kubo T, Rai K, Ichihara E, Hotta K, Tabata M, Toyooka S, Takata M, Maeda Y, Kiura K.

J Thorac Oncol. 2019 Nov;14(11):2009-2018. doi: 10.1016/j.jtho.2019.07.017. Epub 2019 Jul 30.

PMID:
31374369
6.

Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma.

Nakasuka T, Ichihara E, Makimoto G, Maeda Y, Kiura K.

J Thorac Oncol. 2019 Aug;14(8):e168-e169. doi: 10.1016/j.jtho.2019.03.009. No abstract available.

PMID:
31345339
7.

Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.

Iwamoto Y, Ichihara E, Hara N, Nakasuka T, Ando C, Umeno T, Hirabae A, Maeda Y, Kiura K.

Jpn J Clin Oncol. 2019 Aug 1;49(8):786-788. doi: 10.1093/jjco/hyz086.

PMID:
31187861
8.

Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies.

Nishii K, Hotta K, Ninomiya K, Kato Y, Ichihara E, Ohashi K, Ninomiya T, Kubo T, Rai K, Tabata M, Maeda Y, Kiura K.

Respir Investig. 2019 Sep;57(5):460-465. doi: 10.1016/j.resinv.2019.04.004. Epub 2019 Jun 8.

PMID:
31186170
9.

Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.

Ichihara E, Hotta K, Ninomiya K, Kubo T, Ohashi K, Rai K, Tanaka H, Tabata M, Maeda Y, Kiura K.

Lung Cancer. 2019 Jun;132:54-58. doi: 10.1016/j.lungcan.2019.02.021. Epub 2019 Apr 6.

PMID:
31097094
10.

The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.

Watanabe H, Kubo T, Ninomiya K, Kudo K, Minami D, Murakami E, Ochi N, Ninomiya T, Harada D, Yasugi M, Ichihara E, Ohashi K, Fujiwara K, Hotta K, Tabata M, Maeda Y, Kiura K.

Jpn J Clin Oncol. 2019 Aug 1;49(8):762-765. doi: 10.1093/jjco/hyz066.

PMID:
31090906
11.

Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities.

Higo H, Kubo T, Makimoto S, Makimoto G, Ihara H, Masaoka Y, Ninomiya T, Ichihara E, Ohashi K, Sato A, Hotta K, Tabata M, Takigawa N, Maeda Y, Kiura K.

Jpn J Clin Oncol. 2019 May 1;49(5):458-464. doi: 10.1093/jjco/hyz016.

PMID:
30793176
12.

A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.

Oda N, Hotta K, Ninomiya K, Minami D, Ichihara E, Murakami T, Yokoyama T, Ichikawa H, Chikamori K, Takigawa N, Ochi N, Harita S, Maeda Y, Kiura K.

Cancer Chemother Pharmacol. 2018 Dec;82(6):1031-1038. doi: 10.1007/s00280-018-3694-5. Epub 2018 Oct 1.

PMID:
30276451
13.

Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice.

Hotta K, Ninomiya K, Ichihara E, Kiura K.

Int J Clin Oncol. 2019 Jan;24(1):41-45. doi: 10.1007/s10147-018-1344-x. Epub 2018 Aug 29. Review.

PMID:
30159691
14.

Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.

Kato Y, Ninomiya K, Ohashi K, Tomida S, Makimoto G, Watanabe H, Kudo K, Matsumoto S, Umemura S, Goto K, Ichihara E, Ninomiya T, Kubo T, Sato A, Hotta K, Tabata M, Toyooka S, Maeda Y, Kiura K.

Cancer Sci. 2018 Oct;109(10):3149-3158. doi: 10.1111/cas.13752. Epub 2018 Sep 11.

15.

Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer.

Ichihara E, Hotta K, Kubo T, Higashionna T, Ninomiya K, Ohashi K, Tabata M, Maeda Y, Kiura K.

Oncotarget. 2018 Jun 29;9(50):29525-29531. doi: 10.18632/oncotarget.25705. eCollection 2018 Jun 29.

16.

Randomized Phase II Study Comparing Mannitol with Furosemide for the Prevention of Renal Toxicity Induced by Cisplatin-based Chemotherapy with Short-term Low-volume Hydration in Advanced Non-small Cell Lung Cancer: The OLCSG1406 Study Protocol.

Makimoto G, Ichihara E, Hotta K, Ninomiya K, Oze I, Minami D, Ninomiya T, Kubo T, Ohashi K, Tabata M, Maeda Y, Kiura K.

Acta Med Okayama. 2018 Jun;72(3):319-323. doi: 10.18926/AMO/56080.

17.

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib.

Ninomiya K, Ohashi K, Makimoto G, Tomida S, Higo H, Kayatani H, Ninomiya T, Kubo T, Ichihara E, Hotta K, Tabata M, Maeda Y, Kiura K.

Sci Rep. 2018 Jan 31;8(1):1955. doi: 10.1038/s41598-018-20326-z.

18.

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.

Hotta K, Aoe K, Kozuki T, Ohashi K, Ninomiya K, Ichihara E, Kubo T, Ninomiya T, Chikamori K, Harada D, Nogami N, Hirata T, Hinotsu S, Toyooka S, Kiura K.

J Thorac Oncol. 2018 Feb;13(2):273-279. doi: 10.1016/j.jtho.2017.10.032. Epub 2017 Dec 5.

19.

Effects of (-)-epigallocatechin-3-gallate on EGFR- or Fusion Gene-driven Lung Cancer Cells.

Honda Y, Takigawa N, Ichihara E, Ninomiya T, Kubo T, Ochi N, Yasugi M, Murakami T, Yamane H, Tanimoto M, Kiura K.

Acta Med Okayama. 2017 Dec;71(6):505-512. doi: 10.18926/AMO/55587. No abstract available.

20.

A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.

Kuyama S, Ochi N, Bessho A, Hotta K, Ikeda G, Kishino D, Kubo T, Harada D, Fujimoto N, Nakanishi M, Umeno T, Okada T, Chikamori K, Yamagishi T, Ohashi K, Ichihara E, Takigawa N, Tanimoto M, Kiura K.

Lung Cancer. 2017 Oct;112:188-194. doi: 10.1016/j.lungcan.2017.08.010. Epub 2017 Aug 12.

PMID:
29191594
21.

Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations.

Tamura T, Kato Y, Ohashi K, Ninomiya K, Makimoto G, Gotoda H, Kubo T, Ichihara E, Tanaka T, Ichimura K, Maeda Y, Hotta K, Kiura K.

Biochem Biophys Res Commun. 2018 Jan 1;495(1):360-367. doi: 10.1016/j.bbrc.2017.10.175. Epub 2017 Oct 31.

PMID:
29101033
22.

Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease.

Taniguchi A, Miyahara N, Oda N, Morichika D, Ichihara E, Oze I, Tanimoto Y, Ichikawa H, Fujii U, Tanimoto M, Kanehiro A, Kiura K.

Acta Med Okayama. 2017 Oct;71(5):453-457. doi: 10.18926/AMO/55446.

23.

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC).

Watanabe H, Ichihara E, Kano H, Ninomiya K, Tanimoto M, Kiura K.

Intern Med. 2017 Aug 15;56(16):2195-2197. doi: 10.2169/internalmedicine.8344-16. Epub 2017 Aug 1.

24.

Clinical characteristics of Japanese candidates for lung transplant for interstitial lung disease and risk factors for early death while on the waiting list.

Higo H, Kurosaki T, Ichihara E, Kubo T, Miyoshi K, Otani S, Sugimoto S, Yamane M, Miyahara N, Kiura K, Miyoshi S, Oto T.

Respir Investig. 2017 Jul;55(4):264-269. doi: 10.1016/j.resinv.2017.03.002. Epub 2017 Jun 22.

PMID:
28705305
25.

Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis.

Otsubo K, Kishimoto J, Kenmotsu H, Minegishi Y, Ichihara E, Shiraki A, Kato T, Atagi S, Horinouchi H, Ando M, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakanishi Y, Okamoto I.

Clin Lung Cancer. 2018 Jan;19(1):e5-e9. doi: 10.1016/j.cllc.2017.06.003. Epub 2017 Jun 20.

PMID:
28687482
26.

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.

Ichihara E, Westover D, Meador CB, Yan Y, Bauer JA, Lu P, Ye F, Kulick A, de Stanchina E, McEwen R, Ladanyi M, Cross D, Pao W, Lovly CM.

Cancer Res. 2017 Jun 1;77(11):2990-3000. doi: 10.1158/0008-5472.CAN-16-2300. Epub 2017 Apr 17.

27.

Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.

Kudo K, Ohashi K, Makimoto G, Higo H, Kato Y, Kayatani H, Kurata Y, Takami Y, Minami D, Ninomiya T, Kubo T, Ichihara E, Sato A, Hotta K, Yoshino T, Tanimoto M, Kiura K.

Mol Oncol. 2017 Jun;11(6):670-681. doi: 10.1002/1878-0261.12063. Epub 2017 May 2.

28.

Discomfort during bronchoscopy performed after endobronchial intubation with fentanyl and midazolam: a prospective study.

Minami D, Takigawa N, Kano H, Ninomiya T, Kubo T, Ichihara E, Ohashi K, Sato A, Hotta K, Tabata M, Tanimoto M, Kiura K.

Jpn J Clin Oncol. 2017 May 1;47(5):434-437. doi: 10.1093/jjco/hyx022.

PMID:
28334767
29.

Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol.

Ninomiya K, Ichihara E, Hotta K, Sone N, Murakami T, Harada D, Oze I, Kubo T, Tanaka H, Kuyama S, Kishino D, Bessho A, Harita S, Katsui K, Tanimoto M, Kiura K.

Clin Lung Cancer. 2017 Mar;18(2):245-249. doi: 10.1016/j.cllc.2016.08.001. Epub 2016 Oct 19.

PMID:
27847247
30.

Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience.

Oda N, Hotta K, Yoshioka H, Kudo K, Ichihara E, Kato Y, Ninomiya K, Minami D, Ninomiya T, Kubo T, Ohashi K, Sato A, Takigawa N, Tabata M, Tanimoto M, Kiura K.

Cancer Chemother Pharmacol. 2016 Nov;78(5):941-947. Epub 2016 Sep 2.

PMID:
27590708
31.

Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).

Isozaki H, Hotta K, Ichihara E, Takigawa N, Ohashi K, Kubo T, Ninomiya T, Ninomiya K, Oda N, Yoshioka H, Ichikawa H, Inoue M, Takata I, Shibayama T, Kuyama S, Sugimoto K, Harada D, Harita S, Sendo T, Tanimoto M, Kiura K.

Clin Lung Cancer. 2016 Nov;17(6):602-605. doi: 10.1016/j.cllc.2016.05.005. Epub 2016 Jun 2.

PMID:
27405684
32.

Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation.

Osawa M, Ohashi K, Kubo T, Ichihara E, Takata S, Takigawa N, Takata M, Tanimoto M, Kiura K.

Acta Med Okayama. 2016 Aug;70(4):243-53.

33.

Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403.

Oda N, Ichihara E, Hotta K, Ninomiya K, Ninomiya T, Kubo T, Minami D, Murakami T, Yokoyama T, Harada D, Kuyama S, Ichikawa H, Inoue K, Kishino D, Inoue M, Takigawa N, Shibayama T, Harita S, Tanimoto M, Kiura K.

Clin Lung Cancer. 2017 Mar;18(2):241-244. doi: 10.1016/j.cllc.2016.07.003. Epub 2016 Jul 9.

PMID:
27506489
34.

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, Vavalà T, Whiteley A, Chen H, Yan Y, Sheehan JH, Meiler J, Morosini D, Ross JS, Stephens PJ, Miller VA, Ali SM, Lovly CM.

Cancer Discov. 2016 Jun;6(6):601-11. doi: 10.1158/2159-8290.CD-16-0075. Epub 2016 Apr 21.

35.

Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.

Isozaki H, Ichihara E, Takigawa N, Ohashi K, Ochi N, Yasugi M, Ninomiya T, Yamane H, Hotta K, Sakai K, Matsumoto K, Hosokawa S, Bessho A, Sendo T, Tanimoto M, Kiura K.

Cancer Res. 2016 Mar 15;76(6):1506-16. doi: 10.1158/0008-5472.CAN-15-1010. Epub 2015 Dec 30.

36.

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG.

Nat Med. 2015 Sep;21(9):1038-47. doi: 10.1038/nm.3930. Epub 2015 Aug 24.

37.

Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients with Non-Small-Cell Lung Cancer.

Ichihara E, Hotta K, Kiura K.

J Thorac Oncol. 2015 Aug;10(8):e79. doi: 10.1097/JTO.0000000000000583. No abstract available.

38.

Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer.

Ichihara E, Lovly CM.

Cancer Discov. 2015 Jul;5(7):694-6. doi: 10.1158/2159-8290.CD-15-0616.

39.

Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201.

Ninomiya K, Hotta K, Hisamoto-Sato A, Ichihara E, Gotoda H, Morichika D, Tamura T, Kayatani H, Minami D, Kubo T, Tabata M, Tanimoto M, Kiura K.

Int J Clin Oncol. 2016 Feb;21(1):81-7. doi: 10.1007/s10147-015-0860-1. Epub 2015 Jun 21.

PMID:
26093520
40.

Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703.

Kudo K, Hotta K, Ichihara E, Yoshioka H, Kunimasa K, Tsubouchi K, Iwasaku M, Kato Y, Oze I, Takigawa N, Tanimoto M, Kiura K.

Cancer Chemother Pharmacol. 2015 Aug;76(2):251-6. doi: 10.1007/s00280-015-2789-5. Epub 2015 Jun 3.

PMID:
26037206
41.

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, Meador CB, Spitzler P, Ichihara E, Ross SJ, Ahdesmaki MJ, Ahmed A, Ratcliffe LE, O'Brien EL, Barnes CH, Brown H, Smith PD, Dry JR, Beran G, Thress KS, Dougherty B, Pao W, Cross DA.

Cancer Res. 2015 Jun 15;75(12):2489-500. doi: 10.1158/0008-5472.CAN-14-3167. Epub 2015 Apr 13.

42.

Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.

Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, Bessho A, Hisamoto-Sato A, Kubo T, Oze I, Takigawa N, Tanimoto M, Kiura K.

J Thorac Oncol. 2015 Mar;10(3):486-91. doi: 10.1097/JTO.0000000000000434.

43.

A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.

Isozaki H, Yasugi M, Takigawa N, Hotta K, Ichihara E, Taniguchi A, Toyooka S, Hashida S, Sendo T, Tanimoto M, Kiura K.

Jpn J Clin Oncol. 2014 Oct;44(10):963-8. doi: 10.1093/jjco/hyu110. Epub 2014 Aug 28.

PMID:
25170107
44.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W.

Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.

45.

Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors.

Yasugi M, Takigawa N, Ochi N, Ohashi K, Harada D, Ninomiya T, Murakami T, Honda Y, Ichihara E, Tanimoto M, Kiura K.

Exp Cell Res. 2014 Aug 15;326(2):201-9. doi: 10.1016/j.yexcr.2014.04.012. Epub 2014 Apr 25.

46.

Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience.

Kato Y, Hotta K, Takigawa N, Nogami N, Kozuki T, Sato A, Ichihara E, Kudo K, Oze I, Tabata M, Shinkai T, Tanimoto M, Kiura K.

Cancer Chemother Pharmacol. 2014 May;73(5):943-50. doi: 10.1007/s00280-014-2425-9. Epub 2014 Mar 16.

PMID:
24633759
47.

Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer.

Ochi N, Takigawa N, Harada D, Yasugi M, Ichihara E, Hotta K, Tabata M, Tanimoto M, Kiura K.

Exp Cell Res. 2014 Mar 10;322(1):168-77. doi: 10.1016/j.yexcr.2014.01.007. Epub 2014 Jan 15.

48.

Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model.

Murakami T, Takigawa N, Ninomiya T, Ochi N, Yasugi M, Honda Y, Kubo T, Ichihara E, Hotta K, Tanimoto M, Kiura K.

Lung Cancer. 2014 Jan;83(1):30-6. doi: 10.1016/j.lungcan.2013.10.011. Epub 2013 Oct 29.

49.

Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002.

Hotta K, Takigawa N, Hisamoto-Sato A, Ichihara E, Kudo K, Uchida K, Yanase-Nakamura K, Tanaka H, Kato Y, Tabata M, Tanimoto M, Kiura K.

Jpn J Clin Oncol. 2013 Nov;43(11):1115-23. doi: 10.1093/jjco/hyt128. Epub 2013 Sep 29.

PMID:
24082005
50.

Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model.

Hayakawa H, Ichihara E, Ohashi K, Ninomiya T, Yasugi M, Takata S, Sakai K, Matsumoto K, Takigawa N, Tanimoto M, Kiura K.

Cancer Sci. 2013 Nov;104(11):1440-6. doi: 10.1111/cas.12284. Epub 2013 Oct 25.

Supplemental Content

Loading ...
Support Center